​​ Under the scope: Tamoxifen Tamoxifen was first synthesize | Steroidify

​​ Under the scope: Tamoxifen

Tamoxifen was first synthesized in 1962 by scientists at the British pharmaceutical company Imperial Chemical Industries PLC (now AstraZeneca).
It blocks estrogen by attaching to receptor sites in breast tissue and other tissues, like the liver.
It’s not an AI (Aromatase Inhibitor) so it will not lower concentration of estrogen in blood plasma.
It was first used to treat or prevent breast cancer in females, since breast cancer cells are very responsive to the hormone estrogen and is still used for that purpose, but gradually being replaced by AI, such as anastrozole and exemestane.

Class of Drug – Anti Estrogen

Subclass – SERM (Selective Estrogen Receptor Modulator)

Half-life – 5 to 7 days

It was the first drug used in bodybuilding to prevent estrogen effects on the body during a steroid cycle, especially gynecomastia, but now it’s used mainly during PCT (Post Cycle Therapy) alongside clomiphene. Both have shown to work in synergy to increase testosterone natural production after a cycle.
Current choices for keeping estrogen sides under control during cycles are anastrozole, exemestane and letrozole, but a few bodybuilders still use tamoxifen for that purpose, which is now considered an old school approach.

#Underthescope #Nolvadex #PCT